Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04608318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04608318 · ClinicalTrials.gov record · last posted 2026-04-30

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Study acronym: CLL17
StatusActive, Not Recruiting
PhasePhase 3
Started2021-03-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by measuring progression-free survival (PFS) in patients with previously untreated CLL.

Amendment record 10 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 10 times since 2020-10-23; most recent amendment 2026-04-27. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-02-22
Status change Recruiting→Active, Not Recruitingv7
2021-02-12
Status change Not Yet Recruiting→Recruitingv4
Trial Details
NCT Number NCT04608318
Lead Sponsor German CLL Study Group
Collaborators: Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto, Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Conditions Chronic Lymphoid Leukemia
Enrollment 897 participants
Start Date 2021-03-01
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-30